Allosteric Inhibition of CXCR1/2 by an Orally Bioavailable Chemokine Receptor Inhibitor Attenuates Allergic Lung Inflammation in Mice
Journal of Allergy and Clinical Immunology(2023)
摘要
CXCR1/2 chemokine receptors are expressed on the surface of inflammatory cells. We previously reported that parenterally-administered reparixin, a noncompetitive allosteric inhibitor of CXCR1 and CXCR2, inhibits allergic airway inflammation. Ladarixin is a second generation orally bioavailable dual CXCR1/2 inhibitor that binds an allosteric pocket of the trans-membrane region of both receptors with a 100-fold higher affinity than first generation CXCR1/2 inhibitors. Here we investigated whether oral ladarixin also inhibits allergic airway inflammation.
更多查看译文
关键词
Chemokine Receptors
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要